FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1541532008> ?p ?o ?g. }

• W1541532008 endingPage "E468" @default.
• W1541532008 startingPage "E461" @default.
• W1541532008 abstract "What's known on the subject? and What does the study add? Serum C-reactive protein (C-reactive protein) is emerging as a potential novel prognostic factor in metastatic castration-resistant prostate cancer (mCRPC). In the present study, a prospective trial was investigated retrospectively and a significant prognostic impact for C-reactive protein that was independent of multiple published prognostic models was identified in men receiving docetaxel-based chemotherapy for mCRPC. Prospective validation is warranted.• Given the recent emergence of C-reactive protein levels as a novel prognostic factor in men with metastatic castration-resistant prostate cancer (mCRPC), we sought to evaluate the independent prognostic ability of C-reactive protein in the context of published prognostic nomograms, risk grouping and disease state models in men receiving docetaxel-based chemotherapy for mCRPC.• A large randomized phase II trial (CS-205) of mCRPC patients who received docetaxel-prednisone + AT-101 (Bcl-2 inhibitor) or docetaxel-prednisone + placebo was analyzed retrospectively (n= 220). • Overall survival (OS), progression-free survival (PFS) and measures of discriminatory ability were assessed in a hypothesis-generating analysis using Cox regression and concordance probabilities. • Patients from both treatment groups were combined for this analysis because no significant differences in outcomes were observed. • Because some factors used in nomograms were not collected or defined differently, risk was estimated based on slightly modified versions of nomograms.• C-reactive protein was independently prognostic for OS and PFS (P ≤ 0.002) after adjusting for all modeled risk estimates and classifiers. • C-reactive protein showed a concordance probability of 0.65 for both OS and PFS. • A 10-factor modified prognostic model based on the TAX327 trial had the greatest observed discrimination ability for OS and PFS (concordance probability = 0.623 and 0.603, respectively) among the modified nomograms or classifiers. • Adding the TAX327 model risk estimates to C-reactive protein did not substantially increase discrimination ability over C-reactive protein alone.• Current prognostic classifications provide modest discrimination of outcomes in mCRPC receiving docetaxel-based chemotherapy, highlighting the need for improved risk-based models. • Baseline C-reactive protein appears to be an useful, independent prognostic factor and prospective external validation is warranted." @default.
• W1541532008 created "2016-06-24" @default.
• W1541532008 creator A5018275141 @default.
• W1541532008 creator A5021879267 @default.
• W1541532008 creator A5038489185 @default.
• W1541532008 creator A5047689900 @default.
• W1541532008 creator A5052069729 @default.
• W1541532008 creator A5075558949 @default.
• W1541532008 date "2012-04-23" @default.
• W1541532008 modified "2023-10-05" @default.
• W1541532008 title "Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy" @default.
• W1541532008 cites W1972987731 @default.
• W1541532008 cites W1988614578 @default.
• W1541532008 cites W1993060519 @default.
• W1541532008 cites W1993213090 @default.
• W1541532008 cites W2004973733 @default.
• W1541532008 cites W2011092724 @default.
• W1541532008 cites W2045774880 @default.
• W1541532008 cites W2064443885 @default.
• W1541532008 cites W2070396041 @default.
• W1541532008 cites W2080439368 @default.
• W1541532008 cites W2085262248 @default.
• W1541532008 cites W2085739762 @default.
• W1541532008 cites W2086478724 @default.
• W1541532008 cites W2099367648 @default.
• W1541532008 cites W2103090668 @default.
• W1541532008 cites W2103959341 @default.
• W1541532008 cites W2110534364 @default.
• W1541532008 cites W2117783793 @default.
• W1541532008 cites W2118356269 @default.
• W1541532008 cites W2120292596 @default.
• W1541532008 cites W2123510004 @default.
• W1541532008 cites W2123526148 @default.
• W1541532008 cites W2137983259 @default.
• W1541532008 cites W2142200772 @default.
• W1541532008 cites W2148998801 @default.
• W1541532008 cites W2150794592 @default.
• W1541532008 cites W2158453750 @default.
• W1541532008 cites W2160357325 @default.
• W1541532008 cites W2165542862 @default.
• W1541532008 cites W2167331614 @default.
• W1541532008 cites W2167869791 @default.
• W1541532008 cites W2168711381 @default.
• W1541532008 cites W2317931576 @default.
• W1541532008 cites W4232045253 @default.
• W1541532008 doi "https://doi.org/10.1111/j.1464-410x.2012.11148.x" @default.
• W1541532008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22520631" @default.
• W1541532008 hasPublicationYear "2012" @default.
• W1541532008 type Work @default.
• W1541532008 sameAs 1541532008 @default.
• W1541532008 citedByCount "28" @default.
• W1541532008 countsByYear W15415320082012 @default.
• W1541532008 countsByYear W15415320082013 @default.
• W1541532008 countsByYear W15415320082014 @default.
• W1541532008 countsByYear W15415320082015 @default.
• W1541532008 countsByYear W15415320082016 @default.
• W1541532008 countsByYear W15415320082017 @default.
• W1541532008 countsByYear W15415320082018 @default.
• W1541532008 countsByYear W15415320082019 @default.
• W1541532008 countsByYear W15415320082020 @default.
• W1541532008 countsByYear W15415320082021 @default.
• W1541532008 crossrefType "journal-article" @default.
• W1541532008 hasAuthorship W1541532008A5018275141 @default.
• W1541532008 hasAuthorship W1541532008A5021879267 @default.
• W1541532008 hasAuthorship W1541532008A5038489185 @default.
• W1541532008 hasAuthorship W1541532008A5047689900 @default.
• W1541532008 hasAuthorship W1541532008A5052069729 @default.
• W1541532008 hasAuthorship W1541532008A5075558949 @default.
• W1541532008 hasBestOaLocation W15415320081 @default.
• W1541532008 hasConcept C121608353 @default.
• W1541532008 hasConcept C126322002 @default.
• W1541532008 hasConcept C143998085 @default.
• W1541532008 hasConcept C2776694085 @default.
• W1541532008 hasConcept C2776914184 @default.
• W1541532008 hasConcept C2778720950 @default.
• W1541532008 hasConcept C2780192828 @default.
• W1541532008 hasConcept C2781190966 @default.
• W1541532008 hasConcept C2781195455 @default.
• W1541532008 hasConcept C34626388 @default.
• W1541532008 hasConcept C50382708 @default.
• W1541532008 hasConcept C71924100 @default.
• W1541532008 hasConceptScore W1541532008C121608353 @default.
• W1541532008 hasConceptScore W1541532008C126322002 @default.
• W1541532008 hasConceptScore W1541532008C143998085 @default.
• W1541532008 hasConceptScore W1541532008C2776694085 @default.
• W1541532008 hasConceptScore W1541532008C2776914184 @default.
• W1541532008 hasConceptScore W1541532008C2778720950 @default.
• W1541532008 hasConceptScore W1541532008C2780192828 @default.
• W1541532008 hasConceptScore W1541532008C2781190966 @default.
• W1541532008 hasConceptScore W1541532008C2781195455 @default.
• W1541532008 hasConceptScore W1541532008C34626388 @default.
• W1541532008 hasConceptScore W1541532008C50382708 @default.
• W1541532008 hasConceptScore W1541532008C71924100 @default.
• W1541532008 hasIssue "11b" @default.
• W1541532008 hasLocation W15415320081 @default.
• W1541532008 hasLocation W15415320082 @default.
• W1541532008 hasOpenAccess W1541532008 @default.
• W1541532008 hasPrimaryLocation W15415320081 @default.

• next